HANOI, Vietnam -- PRB Pharmaceuticals and Lee's Pharmaceuticals announced today that Vietnam's Department of Animal Health will begin testing an animal version of VIRA 38 on their poultry flocks as part of a multi-national, avian influenza research collaboration. Other members of the group include laboratories and clinics at The Chinese University of Hong Kong, The Prince of Wales Hospital (Hong Kong), and Mahidol University (Thailand).
"Our collaboration with PRB Pharmaceuticals is headed by Dr. To Long Thanh
and is part of Vietnam's continued effort to bring avian influenza under control," said Dr. Bui Quang Anh, director-general of the Department of Animal Health, Vietnam.
The announcement comes amid new concerns that migratory birds will spread the lethal H5N1 virus to poultry and humans, triggering a worldwide influenza pandemic.
"The massive infection and death of migratory birds at China's Qinghai Lake and the emergence of new H5N1 strains is cause for concern," said Dr. Charles Hensley, chairman and CEO of PRB Pharmaceuticals. "The H5N1 virus is gaining momentum and the migratory bird, poultry, human axis is driving the evolution of this virus toward the development of a pandemic strain. A comprehensive approach targeting each component of this axis is desperately needed."
"The nightmare scenario is that new H5N1 variants will emerge that are not only highly contagious in humans but also resistant to existing anti-viral drugs," added Dr. Benjamin Li, CEO of Lee's Pharmaceuticals. "Viral resistance is most likely to occur when a drug targets a single point of the viral life cycle. The H5N1 virus is already resistant to amantadine and the World Health Organization has reported oseltamivir (Tamiflu) resistance in Northern Vietnam."
"Our approach is to attack the virus at multiple points of its life cycle. This results in greater efficacy and reduces the likelihood of the virus developing resistance," added Hensley. "A crucial component of our research program is the testing of VIRA 38 and its fractions against the H5N1 variants emerging in China and Vietnam as well as those showing resistance to oseltamivir (Tamiflu)."
VIRA 38 first gained notoriety during the Taiwan SARS outbreak when it was used by the Taiwan presidential staff and doctors at Sungshan Hospital (SARS management facility) and again in 2004 when it was found to inhibit H5N1 infections.
VIRA 38, PRB Pharmaceuticals' over-the-counter broad spectrum anti-viral medication, is known for its effectiveness in treating and preventing influenza. VIRA 38 has recently been shown to contain compounds that inhibit a variety of pathogens including the bird flu (H5N1) virus.
Source: PRB Pharmaceuticals and Lee's Pharmaceuticals
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.